{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:47:20Z","timestamp":1786718840173,"version":"build-2736575974"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Trichol"],"published-print":{"date-parts":[[2018]]},"DOI":"10.4103\/ijt.ijt_87_18","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T05:45:56Z","timestamp":1548999956000},"page":"286","source":"Crossref","is-referenced-by-count":2,"title":["Suspected herpes zoster-associated encephalitis during treatment with oral tofacitinib in alopecia universalis"],"prefix":"10.4103","volume":"10","author":[{"given":"Anna-Marie","family":"Hosking","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margit","family":"Juh\u00e1sz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NatashaAtanaskova","family":"Mesinkovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0974-7753.251429-1","first-page":"736","volume-title":"JAK inhibitors in dermatology: The promise of a new drug class","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0974-7753.251429-2","first-page":"22","volume-title":"Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0974-7753.251429-3","unstructured":"Kavanaugh A. Real World Results from a Post-Approval Safety Surveillance of Tofacitinib (Xeljanz): Over 3 Year Results from an Ongoing US-Based Rheumatoid Arthritis Registry. ACR Meeting Abstracts. Available from: http:\/\/www.acrabstracts.org\/abstract\/real-world-results-from-a-post-approval-safety-surveillance-of-tofacitinib-xeljanz-over-3-year-results-from-an-ongoing-us-based-rheumatoid-arthritis-registry\/. [Last accessed on 2018 Sep 01]."},{"key":"key-10.4103\/0974-7753.251429-4","first-page":"789","volume-title":"Zoster in the elderly: Clinical, immunologic and therapeutic considerations","author":"Harnisch","year":"1984","journal-title":"J Am Geriatr Soc"},{"key":"key-10.4103\/0974-7753.251429-5","first-page":"356","volume-title":"Neurological complications of varicella zoster virus reactivation","author":"Nagel","year":"2014","journal-title":"Curr Opin Neurol"},{"key":"key-10.4103\/0974-7753.251429-6","first-page":"302","volume-title":"Herpes zoster in psoriasis patients treated with tofacitinib","author":"Winthrop","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0974-7753.251429-7","first-page":"e529","volume-title":"Infection of the central nervous system caused by varicella zoster virus reactivation: A retrospective case series study","author":"Becerra","year":"2013","journal-title":"Int J Infect Dis"},{"key":"key-10.4103\/0974-7753.251429-8","first-page":"206","volume-title":"Diagnosis and management of acute encephalitis: A practical approach","author":"Venkatesan","year":"2014","journal-title":"Neurol Clin Pract"},{"key":"key-10.4103\/0974-7753.251429-9","unstructured":"PFIZER INC. Tofacitinib (CP-690,550) Ulcerative Colitis FDA Advisory Committee Meeting. PFIZER INC.; 2018. Available from: https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/GastrointestinalDrugsAdvisoryCommittee\/UCM599514.pdf. [Last accessed on 2018 Sep 01]."},{"key":"key-10.4103\/0974-7753.251429-10","first-page":"1114","volume-title":"Case definitions, diagnostic algorithms, and priorities in encephalitis: Consensus statement of the international encephalitis consortium","author":"Venkatesan","year":"2013","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Trichology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:40:23Z","timestamp":1786714823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijt.ijt_87_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"alternative-id":["251429"],"URL":"https:\/\/doi.org\/10.4103\/ijt.ijt_87_18","relation":{},"ISSN":["0974-7753"],"issn-type":[{"value":"0974-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}